ALX Oncology press release (ALXO): Q1 GAAP EPS of -$0.17 beats by $0.02. - Cash, Cash Equivalents and Investments:Â Cash, cash equivalents and investments as of March 31, 2026, were $169.1 million. The Company believes its cash, cash equivalents and investments are suffici
ALX Oncology press release (ALXO): Q1 GAAP EPS of -$0.17 beats by $0.02. – Cash, Cash Equivalents and Investments:Â Cash, cash equivalents and investments as of March 31, 2026, were $169.1 million.
The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
